<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39316397</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2574-3805</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>03</Day></PubDate></JournalIssue><Title>JAMA network open</Title><ISOAbbreviation>JAMA Netw Open</ISOAbbreviation></Journal><ArticleTitle>Validation of Administrative Data and Timing of Point Prevalence Surveys for Antibiotic Monitoring.</ArticleTitle><Pagination><StartPage>e2435127</StartPage><MedlinePgn>e2435127</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2435127</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamanetworkopen.2024.35127</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="UNASSIGNED">Point prevalence surveys (PPSs) are used globally to collect data on antibiotic prescriptions. However, the optimal frequency for data collection to ensure comprehensive understanding of antibiotic use and to target and monitor stewardship interventions remains unknown.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To identify the optimal frequency for collecting data on antibiotic use among the pediatric population through PPSs leveraging administrative data.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="UNASSIGNED">This prognostic study used a cross-sectional validation approach and was conducted in pediatric outpatient and inpatient settings in the Veneto region of Italy. Antibiotics were classified according to the World Health Organization Access, Watch and Reserve criteria. Prescribing rates of access antibiotics were analyzed for pediatric inpatients with records dated between October 1, 2014, and December 31, 2022, and outpatients with records dated between January 1, 2010, and December 31, 2022. The study included children younger than 15 years with an antibiotic prescription who were admitted to the pediatric acute care unit or evaluated by a primary care pediatrician. Data analysis was performed from October 2023 to January 2024.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="UNASSIGNED">An algorithm was developed to identify optimal time frames for conducting PPSs. This approach sought to minimize the discrepancy between quarterly and yearly PPS results, aiming to accurately estimate annual antibiotic prescribing rates in both inpatient and outpatient settings (primary outcome). External validity of the optimal PPS time frames derived from outpatient data when applied to the inpatient setting was also investigated. Validation involved assessing the effectiveness of administrative data in identifying strategic PPS periods for capturing inpatient antibiotic use patterns (secondary outcome).</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">This analysis included 106 309 children: 3124 were inpatients (1773 males [56.8%]) and 103 185 were outpatients (53 651 males [52.0%]). A total of 5099 and 474 867 antibiotic prescriptions from inpatients and outpatients were analyzed, respectively. Outpatients tended to be older than inpatients, with a median age of 3.2 (IQR, 1.3-6.3) years vs 2.6 (IQR, 0.6-6.6) years, respectively, and with a lower burden of clinical comorbidities (≥1 comorbidity: 6618 [6.4%] vs 1141 [36.5%], respectively). The algorithm successfully identified distinct time frames within the calendar year from inpatient and outpatient records optimized for PPS data collection. Rates obtained from the quarterly PPS during these identified periods exhibited greater agreement with annual antibiotic prescribing rates (inpatient: r = 0.17, P &lt; .001; and outpatient: r = 0.42, P &lt; .001) than those derived from the yearly PPS (inpatient: r = 0.04, P = .58; and outpatient: r = 0.05, P = .34), with a Δ reduction of up to 89.8% (where Δ represents the percentage point change in antibiotic prescribing rates). Furthermore, the optimal PPS time frames gleaned from the outpatient data demonstrated robust applicability to the inpatient setting, yielding comparable results in both scenarios.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="UNASSIGNED">This study evaluated the potential of administrative data in determining the optimal timing of PPS implementation. The quarterly PPS balanced precision and sustainability, especially when implemented during strategically selected periods across different seasons. Further studies are needed to validate the algorithm used in this study, especially in post-COVID-19 pandemic years and different settings.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boracchini</LastName><ForeName>Riccardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Laboratory of Healthcare Research and Pharmacoepidemiology, Division of Biostatistics, Epidemiology, and Public Health, Department of Statistics and Quantitative Methods, University of Milano-Bicocca, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brigadoi</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Pediatric Infectious Diseases, Department of Women's and Children's Health, University of Padua, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbieri</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Pediatric Infectious Diseases, Department of Women's and Children's Health, University of Padua, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liberati</LastName><ForeName>Cecilia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Pediatric Infectious Diseases, Department of Women's and Children's Health, University of Padua, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossin</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Pediatric Emergency Department, University of Padua, Padua, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Women's and Children's Health, University of Padua, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tesser</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Women's and Children's Health, University of Padua, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiusaroli</LastName><ForeName>Lorenzo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Pediatric Infectious Diseases, Department of Women's and Children's Health, University of Padua, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demarin</LastName><ForeName>Giulia Camilla</ForeName><Initials>GC</Initials><AffiliationInfo><Affiliation>Department of Women's and Children's Health, University of Padua, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maestri</LastName><ForeName>Linda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Women's and Children's Health, University of Padua, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tirelli</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Pediatric Emergency Department, University of Padua, Padua, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Women's and Children's Health, University of Padua, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giaquinto</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Pediatric Infectious Diseases, Department of Women's and Children's Health, University of Padua, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Da Dalt</LastName><ForeName>Liviana</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Pediatric Emergency Department, University of Padua, Padua, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Women's and Children's Health, University of Padua, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bressan</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Pediatric Emergency Department, University of Padua, Padua, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Women's and Children's Health, University of Padua, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cantarutti</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory of Healthcare Research and Pharmacoepidemiology, Division of Biostatistics, Epidemiology, and Public Health, Department of Statistics and Quantitative Methods, University of Milano-Bicocca, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Donà</LastName><ForeName>Daniele</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Pediatric Infectious Diseases, Department of Women's and Children's Health, University of Padua, Padua, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Netw Open</MedlineTA><NlmUniqueID>101729235</NlmUniqueID><ISSNLinking>2574-3805</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="Y">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073602" MajorTopicYN="Y">Antimicrobial Stewardship</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007558" MajorTopicYN="N" Type="Geographic">Italy</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010818" MajorTopicYN="N">Practice Patterns, Physicians'</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011307" MajorTopicYN="N">Drug Prescriptions</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Barbieri reported receiving travel grants from Sanofi and AstraZeneca and grants from the Italian Ministry of University and Research outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>22</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39316397</ArticleId><ArticleId IdType="pmc">PMC11423167</ArticleId><ArticleId IdType="doi">10.1001/jamanetworkopen.2024.35127</ArticleId><ArticleId IdType="pii">2823904</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Qato DM, Alexander GC, Guadamuz JS, Lindau ST. Prescription medication use among children and adolescents in the United States. Pediatrics. 2018;142(3):e20181042. doi:10.1542/peds.2018-1042</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2018-1042</ArticleId><ArticleId IdType="pubmed">30150214</ArticleId></ArticleIdList></Reference><Reference><Citation>Antibiotic use in Italy—national report 2021. Italian Medicines Agency . 2023. Accessed April 30, 2024. https://www.aifa.gov.it/-/l-uso-degli-antibiotici-in-italia-rapporto-nazionale-anno-2021</Citation></Reference><Reference><Citation>Guglielmin M, Muntaner C, O’Campo P, Shankardass K. A scoping review of the implementation of health in all policies at the local level. Health Policy. 2018;122(3):284-292. doi:10.1016/j.healthpol.2017.12.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healthpol.2017.12.005</ArticleId><ArticleId IdType="pubmed">29305241</ArticleId></ArticleIdList></Reference><Reference><Citation>Aabenhus R, Hansen MP, Siersma V, Bjerrum L. Clinical indications for antibiotic use in Danish general practice: results from a nationwide electronic prescription database. Scand J Prim Health Care. 2017;35(2):162-169. doi:10.1080/02813432.2017.1333321</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/02813432.2017.1333321</ArticleId><ArticleId IdType="pmc">PMC5499316</ArticleId><ArticleId IdType="pubmed">28585886</ArticleId></ArticleIdList></Reference><Reference><Citation>Berrevoets MAH, Ten Oever J, Sprong T, et al. . Monitoring, documenting and reporting the quality of antibiotic use in the Netherlands: a pilot study to establish a national antimicrobial stewardship registry. BMC Infect Dis. 2017;17(1):565. doi:10.1186/s12879-017-2673-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-017-2673-5</ArticleId><ArticleId IdType="pmc">PMC5557571</ArticleId><ArticleId IdType="pubmed">28806902</ArticleId></ArticleIdList></Reference><Reference><Citation>Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals. Protocol version 6.1, ECDC PPS 2022-2023. European Centre for Disease Prevention and Control . 2019. Accessed April 30, 2024. https://op.europa.eu/en/publication-detail/-/publication/81130eb7-5fe6-11ed-92ed-01aa75ed71a1/language-en</Citation></Reference><Reference><Citation>WHO methodology for point prevalence survey on antibiotic use in hospitals. World Health Organization . 2018. Accessed July 24, 2024. https://www.who.int/publications/i/item/WHO-EMP-IAU-2018.01</Citation></Reference><Reference><Citation>Yusuf E, Versporten A, Goossens H. Is there any difference in quality of prescribing between antibacterials and antifungals? Results from the first global point prevalence study (Global PPS) of antimicrobial consumption and resistance from 53 countries. J Antimicrob Chemother. 2017;72(10):2906-2909. doi:10.1093/jac/dkx236</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkx236</ArticleId><ArticleId IdType="pubmed">29091210</ArticleId></ArticleIdList></Reference><Reference><Citation>World Medical Association . World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194. doi:10.1001/jama.2013.281053</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2013.281053</ArticleId><ArticleId IdType="pubmed">24141714</ArticleId></ArticleIdList></Reference><Reference><Citation>ENCePP guide on methodological standards in pharmacoepidemiology. European Network of Centres for Pharmacoepidemiology and Pharmacovigilance . Accessed April 30, 2024. https://encepp.europa.eu/encepp-toolkit/methodological-guide_en</Citation></Reference><Reference><Citation>The Pedianet Project . Pedianet. Accessed April 30, 2024. https://pedianet.it</Citation></Reference><Reference><Citation>Batzella E, Cantarutti A, Caranci N, Giaquinto C, Barbiellini Amidei C, Canova C. The association between pediatric COVID-19 vaccination and socioeconomic position: nested case-control study from the Pedianet Veneto cohort. JMIR Public Health Surveill. 2023;9(9):e44234. doi:10.2196/44234</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/44234</ArticleId><ArticleId IdType="pmc">PMC9897308</ArticleId><ArticleId IdType="pubmed">36645419</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturkenboom M, Braeye T, van der Aa L, et al. . ADVANCE database characterisation and fit for purpose assessment for multi-country studies on the coverage, benefits and risks of pertussis vaccinations. Vaccine. 2020;38(suppl 2):B8-B21. doi:10.1016/j.vaccine.2020.01.100</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2020.01.100</ArticleId><ArticleId IdType="pubmed">32061385</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharland M, Gandra S, Huttner B, et al. ; EML Expert Committee and Antibiotic Working Group . Encouraging AWaRe-ness and discouraging inappropriate antibiotic use-the new 2019 Essential Medicines List becomes a global antibiotic stewardship tool. Lancet Infect Dis. 2019;19(12):1278-1280. doi:10.1016/S1473-3099(19)30532-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(19)30532-8</ArticleId><ArticleId IdType="pubmed">31782385</ArticleId></ArticleIdList></Reference><Reference><Citation>AWaRe classification of antibiotics for evaluation and monitoring of use. World Health Organization . 2023. Accessed April 11, 2024. https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.04</Citation></Reference><Reference><Citation>Barbieri E, Liberati C, Cantarutti A, et al. . Antibiotic prescription patterns in the paediatric primary care setting before and after the COVID-19 pandemic in Italy: an analysis using the AWaRe metrics. Antibiotics (Basel). 2022;11(4):457. doi:10.3390/antibiotics11040457</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics11040457</ArticleId><ArticleId IdType="pmc">PMC9025823</ArticleId><ArticleId IdType="pubmed">35453209</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrobial stewardship programmes in health-care facilities in low- and middle-income countries: a practical toolkit. World Health Organization . 2019. Accessed April 11, 2024. https://www.who.int/publications/i/item/9789241515481</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8210188</ArticleId><ArticleId IdType="pubmed">34222945</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitkäpaasi M, Lehtinen JM, Kanerva M. Point prevalence survey is useful for introducing effective surveillance of healthcare-associated infections. Infect Prev Pract. 2021;3(4):100182. doi:10.1016/j.infpip.2021.100182</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.infpip.2021.100182</ArticleId><ArticleId IdType="pmc">PMC8627978</ArticleId><ArticleId IdType="pubmed">34877524</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SB, Thirion DJG, Irfan N, et al. . Antimicrobial utilization data: does point prevalence data correlate with defined daily doses? Infect Control Hosp Epidemiol. 2019;40(8):920-921. doi:10.1017/ice.2019.154</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/ice.2019.154</ArticleId><ArticleId IdType="pubmed">31182182</ArticleId></ArticleIdList></Reference><Reference><Citation>German GJ, Frenette C, Caissy JA, et al. . The 2018 Global Point Prevalence Survey of antimicrobial consumption and resistance in 47 Canadian hospitals: a cross-sectional survey. CMAJ Open. 2021;9(4):E1242-E1251. doi:10.9778/cmajo.20200274</Citation><ArticleIdList><ArticleId IdType="doi">10.9778/cmajo.20200274</ArticleId><ArticleId IdType="pmc">PMC8695542</ArticleId><ArticleId IdType="pubmed">34933882</ArticleId></ArticleIdList></Reference><Reference><Citation>Le A, Han BH, Palamar JJ. When national drug surveys “take too long”: an examination of who is at risk for survey fatigue. Drug Alcohol Depend. 2021;225:108769. doi:10.1016/j.drugalcdep.2021.108769</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drugalcdep.2021.108769</ArticleId><ArticleId IdType="pmc">PMC8282613</ArticleId><ArticleId IdType="pubmed">34049103</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Zhao JY, Shan X, et al. ; Chinese Group on Point-Prevalence Survey of Healthcare-Associated Infections . A point-prevalence survey of healthcare-associated infection in fifty-two Chinese hospitals. J Hosp Infect. 2017;95(1):105-111. doi:10.1016/j.jhin.2016.08.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhin.2016.08.010</ArticleId><ArticleId IdType="pubmed">28007308</ArticleId></ArticleIdList></Reference><Reference><Citation>Yogo N, Greenwood KL, Thompson L, et al. . Point prevalence survey to evaluate the seropositivity for coronavirus disease 2019 (COVID-19) among high-risk healthcare workers. Infect Control Hosp Epidemiol. 2021;42(10):1260-1265. doi:10.1017/ice.2020.1370</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/ice.2020.1370</ArticleId><ArticleId IdType="pmc">PMC7783086</ArticleId><ArticleId IdType="pubmed">33317655</ArticleId></ArticleIdList></Reference><Reference><Citation>Lumley SF, Richens N, Lees E, et al. . Changes in paediatric respiratory infections at a UK teaching hospital 2016-2021; impact of the SARS-CoV-2 pandemic. J Infect. 2022;84(1):40-47. doi:10.1016/j.jinf.2021.10.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2021.10.022</ArticleId><ArticleId IdType="pmc">PMC8591975</ArticleId><ArticleId IdType="pubmed">34757137</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida T, Guimarães JT, Rebelo S. Epidemiological changes in respiratory viral infections in children: the influence of the COVID-19 pandemic. Viruses. 2023;15(9):1880. doi:10.3390/v15091880</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15091880</ArticleId><ArticleId IdType="pmc">PMC10537173</ArticleId><ArticleId IdType="pubmed">37766285</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>